Uncovering the precise role of AFAP1-AS1/AUF1/HER-2 regulatory axis in trastuzumab resistance will not only increase our knowledge of noncoding RNAs-regulated therapeutic effect in cancer and the underlying regulatory mechanism, but also help develop more efficient strategies to reverse chemoresistance. The gene discussed is ERBB2; the disease is cancer.